Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this retrospective study, the effect of intraoperative magnesium sulfate infusion on the incidence of postoperative emergence agitation was evaluated in adult patients who underwent elective lumbar microdiscectomy under general anesthesia. The medical records of patients aged 18-70 years with an ASA physical status of I-II were retrospectively reviewed. Patients were evaluated according to whether they received intraoperative magnesium sulfate infusion as part of anesthetic management. The primary outcome measure was the incidence of emergence agitation in the post-anesthesia care unit; this assessment was based on Ramsay Sedation Scale scores recorded in the post-anesthesia care unit at admission and at 5, 10, 15, and 30 minutes. Secondary outcome measures included postoperative pain scores assessed using the Numeric Rating Scale, intraoperative remifentanil consumption, recovery and extubation times, tramadol requirement in the post-anesthesia care unit, and possible adverse events related to magnesium infusion.
This retrospective study was conducted at Giresun Training and Research Hospital. The aim of the study was to evaluate the effect of intraoperative magnesium sulfate infusion on postoperative emergence agitation in patients undergoing elective lumbar microdiscectomy under general anesthesia.
After institutional ethics committee approval was obtained, the medical records of adult patients aged 18-70 years, classified as ASA physical status I or II, who underwent single-level elective lumbar microdiscectomy under general anesthesia were retrospectively reviewed.
Patients were evaluated in two groups according to intraoperative anesthetic management:
Magnesium Group (Group M): Patients who received a 30 mg/kg intravenous bolus of magnesium sulfate over 15 minutes after induction, followed by a continuous magnesium sulfate infusion at a dose of 10 mg/kg/h until the end of surgery.
Control Group (Group K): Patients who did not receive magnesium sulfate infusion and were managed with a standard anesthesia protocol.
The primary outcome measure was the incidence of emergence agitation in the post-anesthesia care unit (PACU). Emergence agitation was retrospectively assessed from PACU records using the Ramsay Sedation Scale (RSS) at admission to the PACU (T0) and at 5 (T1), 10 (T2), 15 (T3), and 30 (T4) minutes after admission.
Secondary outcome measures included Numeric Rating Scale (NRS) pain scores recorded at the same PACU time points, total intraoperative remifentanil consumption, recovery time defined as the time from discontinuation of sevoflurane to eye opening, extubation time defined as the time from discontinuation of sevoflurane to extubation, meperidine requirement in the PACU, and possible adverse events related to magnesium infusion. These adverse events included arrhythmia, prolonged neuromuscular blockade, and respiratory difficulty.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Magnesium Sulfate Infusion | Patients who underwent elective single-level lumbar microdiscectomy under general anesthesia and received intraoperative magnesium sulfate infusion as part of anesthetic management were included in this group. Magnesium sulfate was administered as a 30 mg/kg intravenous bolus over 15 minutes after induction, followed by a continuous infusion at 10 mg/kg/h until the end of surgery.Intraoperative magnesium sulfate infusion was retrospectively evaluated. Magnesium sulfate had been administered as part of routine anesthetic management and was not an intervention assigned by the investigators for the purpose of this retrospective study. |
| |
| 0.9% Saline Infusion | Patients who underwent elective single-level lumbar microdiscectomy under general anesthesia and did not receive intraoperative magnesium sulfate infusion were included in this group. These patients were managed with the standard anesthesia protocol.Patients in this group had not received intraoperative magnesium sulfate infusion. Standard anesthetic management was retrospectively evaluated from medical records and was not an intervention assigned by the investigators for the purpose of this retrospective study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Magnesium Sulfate Infusion | Drug | Magnesium Sulfate (Experimental Group) Intravenous bolus of magnesium sulfate 30 mg/kg administered over 15 minutes immediately after induction of general anesthesia, followed by continuous infusion at 10 mg/kg/h until the end of surgery. Solutions were prepared in identical syringes and infusion bags by an anesthesia technician not involved in patient care. The preparation and administration protocol ensured blinding of participants, anesthesia providers, and outcome assessors. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Emergence Agitation in the PACU | Percentage of participants with a Ramsay Sedation Scale (RSS) score ≥5, indicating emergence agitation, in the post-anesthesia care unit (PACU) | At PACU admission (T0) and at 5, 10, 15, and 30 minutes post-admission. |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Pain Scores in PACU | Numeric Rating Scale (NRS) pain scores ranging from 0 (no pain) to 10 (worst pain). | At PACU admission (T0) and at 5, 10, 15, and 30 minutes post-admission. |
Not provided
Inclusion Criteria:
Age between 18 and 70 years
ASA physical status classification I or II
Scheduled for elective single-level lumbar microdiscectomy under general anesthesia
Ability to provide written informed consent
Exclusion Criteria:
Severe cardiovascular disease
History of psychiatric disorder
Neuromuscular disease
Pregnancy or breastfeeding
Hepatic or renal dysfunction
Current use of calcium channel blockers, hypnotics, anxiolytics, or antipsychotic medications
Known allergy to magnesium sulfate or study-related medications
Refusal to participate in the study
Not provided
Not provided
Adult patients aged 18-70 years with an ASA physical status of I or II who underwent elective single-level lumbar microdiscectomy under general anesthesia at Giresun Training and Research Hospital were included in the study population. The study population consisted of patients whose medical records contained complete perioperative and post-anesthesia care unit data required for the retrospective evaluation of intraoperative magnesium sulfate infusion and postoperative emergence agitation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| İlke tamdoğan, MD | Contact | +905062916678 | drilkeipek@gmail.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | 1. McKeown, A., & Agarwala, R. (2020). "Emergence agitation: Recognition, prevention, and treatment." BJA Education, 20(6), 180-184. https://doi.org/10.1016/j.bjae.2020.03.002 | ||
| 20526708 | Result | Yu D, Chai W, Sun X, Yao L. Emergence agitation in adults: risk factors in 2,000 patients. Can J Anaesth. 2010 Sep;57(9):843-8. doi: 10.1007/s12630-010-9338-9. Epub 2010 Jun 5. | |
| Result | Soltész, P., Silvasti, M., & Taivainen, T. (2013). "Emergence agitation in adults after general anesthesia: A comparison of sevoflurane and propofol." Acta Anaesthesiologica Scandinavica, 57(3), 315-321. https://doi.org/10.1111/aas.12047 |
Not provided
Not provided
Individual participant data will not be shared due to privacy concerns and institutional policies.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007405 | Intervertebral Disc Displacement |
| D000071257 | Emergence Delirium |
| D011183 | Postoperative Complications |
| ID | Term |
|---|---|
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D006547 | Hernia |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 0.9% Saline Infusion | Drug | ntravenous bolus and continuous infusion of 0.9% sodium chloride solution in the same volume, infusion rate, and duration as the magnesium sulfate group. Solutions were indistinguishable in appearance and prepared under the same blinding procedures. |
|
| D020763 |
| Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003693 | Delirium |
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D010335 | Pathologic Processes |
| D012816 | Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |